Dimensional Fund Advisors LP Makes New Investment in MoonLake Immunotherapeutics (NASDAQ:MLTX)

Dimensional Fund Advisors LP bought a new stake in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 64,384 shares of the company's stock, valued at approximately $3,485,000. Dimensional Fund Advisors LP owned about 0.10% of MoonLake Immunotherapeutics as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. KLP Kapitalforvaltning AS bought a new position in MoonLake Immunotherapeutics during the 4th quarter worth about $244,000. PEAK6 LLC bought a new position in MoonLake Immunotherapeutics during the 4th quarter worth about $271,000. Mariner LLC bought a new position in MoonLake Immunotherapeutics during the 4th quarter worth about $272,000. Barclays PLC increased its holdings in MoonLake Immunotherapeutics by 1,269.2% during the 3rd quarter. Barclays PLC now owns 5,641 shares of the company's stock worth $283,000 after purchasing an additional 5,229 shares in the last quarter. Finally, Teacher Retirement System of Texas increased its holdings in MoonLake Immunotherapeutics by 18.4% during the 4th quarter. Teacher Retirement System of Texas now owns 6,532 shares of the company's stock worth $354,000 after purchasing an additional 1,013 shares in the last quarter. Institutional investors own 93.85% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on MLTX. Wedbush restated an "outperform" rating and issued a $80.00 price objective (up previously from $78.00) on shares of MoonLake Immunotherapeutics in a report on Tuesday, May 13th. The Goldman Sachs Group decreased their price objective on MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating for the company in a report on Thursday, February 27th. Needham & Company LLC reiterated a "buy" rating and issued a $66.00 target price on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 13th. Royal Bank of Canada assumed coverage on shares of MoonLake Immunotherapeutics in a research note on Tuesday, March 18th. They issued an "outperform" rating and a $67.00 target price for the company. Finally, HC Wainwright reiterated a "buy" rating and issued a $100.00 target price on shares of MoonLake Immunotherapeutics in a research note on Thursday, February 27th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $78.71.

MoonLake Immunotherapeutics Trading Up 4.2%

MLTX stock traded up $1.58 during mid-day trading on Monday, hitting $39.20. 270,325 shares of the company were exchanged, compared to its average volume of 356,007. The business has a 50 day simple moving average of $38.40 and a 200-day simple moving average of $44.65. The stock has a market capitalization of $2.51 billion, a PE ratio of -30.39 and a beta of 1.31. MoonLake Immunotherapeutics has a 1-year low of $31.42 and a 1-year high of $58.26.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.13. During the same quarter in the prior year, the firm earned ($0.22) EPS. Equities research analysts expect that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.